Seeyond Has $104,000 Stock Holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Posted by Defense World Staff on Jun 10th, 2023

Seeyond lessened its position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Get Rating) by 93.4% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 438 shares of the biopharmaceutical company’s stock after selling 6,189 shares during the quarter. Seeyond’s holdings in Alnylam Pharmaceuticals were worth $104,000 at the end of the most recent quarter.

Several other large investors have also made changes to their positions in ALNY. Captrust Financial Advisors lifted its holdings in Alnylam Pharmaceuticals by 4.3% during the 2nd quarter. Captrust Financial Advisors now owns 1,285 shares of the biopharmaceutical company’s stock worth $187,000 after purchasing an additional 53 shares during the last quarter. Ieq Capital LLC increased its stake in Alnylam Pharmaceuticals by 4.0% during the 4th quarter. Ieq Capital LLC now owns 1,447 shares of the biopharmaceutical company’s stock worth $344,000 after acquiring an additional 55 shares during the period. Signaturefd LLC increased its stake in Alnylam Pharmaceuticals by 3.8% during the 4th quarter. Signaturefd LLC now owns 1,604 shares of the biopharmaceutical company’s stock worth $381,000 after acquiring an additional 59 shares during the period. Gulf International Bank UK Ltd increased its stake in Alnylam Pharmaceuticals by 0.4% during the 4th quarter. Gulf International Bank UK Ltd now owns 19,986 shares of the biopharmaceutical company’s stock worth $4,749,000 after acquiring an additional 75 shares during the period. Finally, Belpointe Asset Management LLC bought a new position in Alnylam Pharmaceuticals during the 4th quarter worth $25,000.

Insider Transactions at Alnylam Pharmaceuticals

In other news, CEO Yvonne Greenstreet sold 7,615 shares of the company’s stock in a transaction on Thursday, April 27th. The shares were sold at an average price of $194.59, for a total value of $1,481,802.85. Following the transaction, the chief executive officer now owns 30,332 shares of the company’s stock, valued at $5,902,303.88. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. In related news, CFO Jeffrey V. Poulton sold 977 shares of the stock in a transaction on Thursday, April 27th. The stock was sold at an average price of $194.59, for a total value of $190,114.43. Following the transaction, the chief financial officer now owns 11,706 shares of the company’s stock, valued at $2,277,870.54. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CEO Yvonne Greenstreet sold 7,615 shares of the stock in a transaction on Thursday, April 27th. The shares were sold at an average price of $194.59, for a total value of $1,481,802.85. Following the completion of the transaction, the chief executive officer now directly owns 30,332 shares in the company, valued at approximately $5,902,303.88. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 17,799 shares of company stock valued at $3,517,442. 1.40% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on the company. Morgan Stanley lifted their price target on Alnylam Pharmaceuticals from $205.00 to $210.00 and gave the company an “equal weight” rating in a research note on Tuesday, April 4th. Sumitomo Mitsui Financial Group started coverage on Alnylam Pharmaceuticals in a report on Wednesday, April 26th. They set a “neutral” rating and a $220.00 price objective on the stock. Canaccord Genuity Group cut their price objective on Alnylam Pharmaceuticals from $310.00 to $291.00 and set a “buy” rating on the stock in a report on Friday, February 24th. Chardan Capital reissued a “buy” rating and set a $250.00 price objective on shares of Alnylam Pharmaceuticals in a report on Friday, February 24th. Finally, EF Hutton Acquisition Co. I began coverage on Alnylam Pharmaceuticals in a report on Tuesday, February 21st. They set a “buy” rating and a $304.00 price objective on the stock. Six equities research analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company. Based on data from MarketBeat, Alnylam Pharmaceuticals has an average rating of “Moderate Buy” and an average target price of $247.20.

Alnylam Pharmaceuticals Price Performance

NASDAQ:ALNY opened at $190.83 on Friday. The company has a market cap of $23.76 billion, a P/E ratio of -21.96 and a beta of 0.48. The stock’s fifty day moving average price is $198.86 and its two-hundred day moving average price is $210.33. Alnylam Pharmaceuticals, Inc. has a 1 year low of $122.57 and a 1 year high of $242.97.

Alnylam Pharmaceuticals (NASDAQ:ALNY – Get Rating) last posted its earnings results on Thursday, May 4th. The biopharmaceutical company reported ($1.40) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.97) by $0.57. The firm had revenue of $319.29 million for the quarter, compared to the consensus estimate of $312.53 million. Alnylam Pharmaceuticals had a negative return on equity of 1,287.80% and a negative net margin of 93.13%. The business’s quarterly revenue was up 49.7% on a year-over-year basis. During the same quarter in the prior year, the business posted ($2.00) earnings per share. On average, analysts expect that Alnylam Pharmaceuticals, Inc. will post -6.46 earnings per share for the current fiscal year.

Alnylam Pharmaceuticals Profile

(Get Rating)

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases.